**
Millions of Medicare beneficiaries will soon have an opportunity to access weight-loss medications at a significantly reduced cost, thanks to a new pilot programme set to commence on July 1. This initiative, known as the “Medicare GLP-1 Bridge,” will allow eligible participants to obtain popular medications from Novo Nordisk and Eli Lilly, such as Wegovy and Zepbound, for just £50 a month.
Details of the Pilot Programme
The Medicare GLP-1 Bridge aims to provide affordable access to glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that have been shown to assist in weight loss. These drugs can lead to substantial weight reductions—averaging nearly 21 percent of body weight over 72 weeks—making them a valuable option for those struggling with obesity. With the typical cost of these medications often reaching hundreds of pounds monthly, this government initiative is a significant step toward addressing the affordability barrier that many seniors face.
Dr. Mehmet Oz, Administrator of the Centres for Medicare & Medicaid Services (CMS), expressed his commitment to improving access to these necessary treatments. “These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost,” he noted during last month’s announcement.
Who Qualifies for the Programme?
The pilot programme is tailored for individuals aged 65 and older, as well as younger adults with disabilities, who are enrolled in Medicare Part D prescription drug plans. This accounts for over half of the 56 million individuals covered under this scheme. However, eligibility is limited to those whose health is endangered by obesity. Some individuals with prediabetes, excess weight, or a history of cardiovascular issues may also qualify.
Certain groups, such as those already receiving GLP-1 medication through Medicare or those diagnosed with Type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, will not be eligible for this pilot programme.
Available Medications
Participants in the Medicare GLP-1 Bridge will have access to three specific medications: Wegovy, Zepbound, and Foundayo, the latter being Eli Lilly’s oral option for those hesitant about injections. These medications are not only effective but also present less invasive alternatives for weight management.
Zepbound, in particular, has been highlighted for its effectiveness, offering a powerful solution for those grappling with obesity. Patients can expect substantial weight loss results, which underscores the significance of having these options covered under Medicare.
How to Obtain the Medications
The programme will be available nationwide, allowing eligible individuals from all states and territories to participate. To access the medications, patients must obtain a prescription from their healthcare provider, who will also need to complete prior authorisation—a process that ensures the treatment is part of a broader lifestyle programme focusing on diet and exercise.
Once approved, participants can receive coverage for their selected GLP-1 medications until December 31, 2027, unless they switch to a different medication within this category. However, the long-term future of the programme remains uncertain, particularly concerning what will happen when the pilot ends.
Why is This Initiative Temporary?
The necessity for this pilot programme arises from existing federal law prohibiting Medicare from covering these weight-loss drugs outright. The current administration is utilising its authority to establish a temporary demonstration project to explore new payment models and coverage options.
Health policy expert Stacie Dusetzina has raised concerns about the implications of this temporary arrangement, suggesting that once the programme concludes, beneficiaries may struggle to afford these medications, potentially leading to weight regain and adverse health outcomes.
As the pilot programme unfolds, the potential benefits for millions of Americans could be significant, providing crucial support for those battling obesity and related health issues.
Why it Matters
This initiative represents a critical shift in how weight-loss medications are approached within the Medicare system, highlighting a growing recognition of the importance of accessible healthcare solutions. With obesity rates continuing to climb, the ability to afford effective treatments can profoundly impact individual health outcomes and overall public health. As this programme progresses, it may serve as a model for future healthcare policies aimed at improving accessibility to essential medications.
